JP2016175884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016175884A5 JP2016175884A5 JP2015059041A JP2015059041A JP2016175884A5 JP 2016175884 A5 JP2016175884 A5 JP 2016175884A5 JP 2015059041 A JP2015059041 A JP 2015059041A JP 2015059041 A JP2015059041 A JP 2015059041A JP 2016175884 A5 JP2016175884 A5 JP 2016175884A5
- Authority
- JP
- Japan
- Prior art keywords
- fibroma
- neural
- neurofibroma
- external
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010016629 fibroma Diseases 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- 230000001537 neural effect Effects 0.000 claims 4
- 201000004404 Neurofibroma Diseases 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000002674 ointment Substances 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- 239000003860 topical agent Substances 0.000 claims 2
- 210000005036 nerve Anatomy 0.000 claims 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015059041A JP6541124B2 (ja) | 2015-03-23 | 2015-03-23 | びまん性神経線維腫用の外用薬 |
| CN201680030048.4A CN107708694A (zh) | 2015-03-23 | 2016-03-09 | 弥漫性神经纤维瘤用的外用药 |
| US15/559,322 US10117857B2 (en) | 2015-03-23 | 2016-03-09 | External medicine for diffuse plexiform neurofibroma |
| PCT/JP2016/057330 WO2016152519A1 (ja) | 2015-03-23 | 2016-03-09 | びまん性神経線維腫用の外用薬 |
| ES16768422T ES2827953T3 (es) | 2015-03-23 | 2016-03-09 | Medicamento externo para neurofibroma plexiforme difuso |
| EP16768422.4A EP3275441B1 (en) | 2015-03-23 | 2016-03-09 | External medicine for diffuse plexiform neurofibroma |
| HK18110308.6A HK1250917A1 (zh) | 2015-03-23 | 2016-03-09 | 弥漫性神经纤维瘤用的外用药 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015059041A JP6541124B2 (ja) | 2015-03-23 | 2015-03-23 | びまん性神経線維腫用の外用薬 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016175884A JP2016175884A (ja) | 2016-10-06 |
| JP2016175884A5 true JP2016175884A5 (cg-RX-API-DMAC7.html) | 2018-04-26 |
| JP6541124B2 JP6541124B2 (ja) | 2019-07-10 |
Family
ID=56978382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015059041A Expired - Fee Related JP6541124B2 (ja) | 2015-03-23 | 2015-03-23 | びまん性神経線維腫用の外用薬 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10117857B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3275441B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6541124B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107708694A (cg-RX-API-DMAC7.html) |
| ES (1) | ES2827953T3 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1250917A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016152519A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220142990A1 (en) * | 2019-02-27 | 2022-05-12 | Osaka University | External preparation for treating a vascular anomaly |
| CA3153921A1 (en) * | 2019-10-16 | 2021-04-22 | Mari KANEDA | External preparation for treating epilepsy or autism spectrum disorder |
| CN113332228B (zh) * | 2021-04-29 | 2023-03-31 | 杭州中美华东制药有限公司 | 一种西罗莫司凝胶制剂 |
| DE102023119976A1 (de) * | 2023-07-27 | 2025-01-30 | Nobelpharma Co., Ltd. | Rapamycin-haltige pharmazeutische zusammensetzung |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060160837A1 (en) * | 2004-12-29 | 2006-07-20 | The Brigham And Women's Hospital, Inc. | Rapamycin compounds in the treatment of neurofibromatosis type 1 |
| CN101155577B (zh) * | 2005-02-02 | 2015-04-22 | 耐克斯詹尼克斯医药有限公司 | 神经纤维瘤的局部治疗 |
| ES2672627T3 (es) * | 2006-02-02 | 2018-06-15 | Novartis Ag | Tratamiento de la esclerosis tuberosa |
| ES2507078T3 (es) * | 2007-08-16 | 2014-10-14 | Santen Pharmaceutical Co., Ltd | Formulaciones de rapamicina para tratamiento de la degeneración macular relacionada con la edad |
| US20130317053A1 (en) | 2011-01-31 | 2013-11-28 | Osaka University | Externally-used drug for treating skin disorder and method for producing same |
-
2015
- 2015-03-23 JP JP2015059041A patent/JP6541124B2/ja not_active Expired - Fee Related
-
2016
- 2016-03-09 WO PCT/JP2016/057330 patent/WO2016152519A1/ja not_active Ceased
- 2016-03-09 HK HK18110308.6A patent/HK1250917A1/zh unknown
- 2016-03-09 ES ES16768422T patent/ES2827953T3/es active Active
- 2016-03-09 US US15/559,322 patent/US10117857B2/en not_active Expired - Fee Related
- 2016-03-09 EP EP16768422.4A patent/EP3275441B1/en not_active Not-in-force
- 2016-03-09 CN CN201680030048.4A patent/CN107708694A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000117A (es) | Nuevos derivados de quinolina | |
| CA2956871C (en) | Compounds active towards bromodomains | |
| EP4596041A3 (en) | Farnesoid x receptor agonists and uses thereof | |
| MX2016016666A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| MX2016015093A (es) | Derivados de acido boronico y sus usos terapeuticos. | |
| WO2015077503A8 (en) | Autotaxin inhibitor compounds | |
| IL268850A (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
| PH12018500586B1 (en) | Farnesoid x receptor agonists and uses thereof | |
| WO2014205389A8 (en) | Nuclear transport modulators and uses thereof | |
| WO2015153959A3 (en) | Small molecule inhibitors of mcl-1 and uses thereof | |
| WO2017194782A3 (en) | Therapeutic targeting of non-cellular structures | |
| MX2015008627A (es) | Derivados de acido boronico y usos terapeuticos de los mismos. | |
| WO2016004305A3 (en) | Inhibitors of bruton's tyrosine kinase | |
| JP2016147915A5 (cg-RX-API-DMAC7.html) | ||
| WO2015148415A3 (en) | Use of the fl118 core chemical structure platform to generate fl118 derivatives for treatment of human disease | |
| HUE052332T2 (hu) | Heteroaril-származék vagy gyógyászatilag elfogadható sója, eljárás annak elõállítására, és az ezeket hatóanyagént tartalmazó gyógyászati készítmény PI3 kinázokkal összefüggõ betegségek megelõzésére vagy kezelésére | |
| WO2015066302A3 (en) | Compositions, methods of use, and methods of treatment | |
| WO2016191458A3 (en) | Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment | |
| WO2015015378A3 (en) | Heterobicycloaryl rorc2 inhibitors and methods of use thereof | |
| WO2015117841A3 (en) | Meta-stable o/w emulsions | |
| WO2017037075A8 (de) | Zusammensetzung enthaltend einen extrakt aus echinacea und linolsäurederivate | |
| WO2017121646A8 (en) | 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
| WO2015106215A3 (en) | Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same | |
| JP2016175884A5 (cg-RX-API-DMAC7.html) | ||
| WO2016030899A8 (en) | Methods of treating amyotrophic lateral scleroses |